Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.63 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013330 | 0.82 | CNR1 (0.60) | CNR1SERPINE1MGLLKCNK3KCNK9 | |
| SCHEMBL23880579 | 0.82 | GPR35 (0.74) | CNR1GPR35MGLLPTPN11PTPN1 | |
| SCHEMBL31147020 | 0.82 | GPR35 (0.74) | CNR1GPR35MGLLPTPN11PTPN1 | |
| SCHEMBL1015834 | 0.80 | CNR1 (0.54) | CNR1SERPINE1GPR35 | |
| SCHEMBL27964990 | 0.79 | CNR1 (0.64) | CNR1SERPINE1MGLLKCNK3KCNK9 | |
| SCHEMBL1015149 | 0.78 | SERPINE1 (1.00) | CNR1SERPINE1PTPN1 | |
| SCHEMBL29492571 | 0.78 | SERPINE1 (1.00) | CNR1SERPINE1PTPN1 | |
| SCHEMBL20557721 | 0.77 | CNR1 (1.00) | CNR1SERPINE1 | |
| SCHEMBL30469260 | 0.77 | CNR1 (1.00) | CNR1SERPINE1 | |
| SCHEMBL13065682 | 0.76 | CNR1 (0.56) | CNR1SERPINE1KCNK3KCNK9HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415479-B2 | Inhibitor of plasminogen activator inhibitor-1 | RENASCIENCE CO., LTD. (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | RENASCIENCE CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2272822-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | Renascience CO., LTD. (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112140-A1 | INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 | SERPINE1, SERPINB1, SERPINC1 | CNR1 3950/4885SERPINE1 1/4885GPR35 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.